Pandemic Influenza Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), By Application (6 Months to 3 Years, > 3 Years) and Regional Forecast to 2033

PANDEMIC INFLUENZA VACCINE MARKET REPORT OVERVIEW

The global Pandemic Influenza Vaccine Market is anticipated to witness consistent growth, starting at USD 6.00 billion in 2024, reaching USD 6.33 billion in 2025, and climbing to USD 9.40 billion by 2033, with a steady CAGR of 5.5% from 2025 to 2033.

A viral infection caused by influenza flu is known as pandemic influenza. This flu can penetrate into the body through the respiratory system and keeps moving inside the body. This can be transmitted to other people through physical contact or by communication. It can be moderate to severe level which can lead to death of the individual.

The intensifying apprehension and the increasing rate of the infection in the people have increased the demand for this flu vaccine tremendously. Government investment and support provides many chances along with major companies spending on R&D are giving many opportunities for market growth.

KEY FINDINGS

• Market Size and Growth (2025–2033): The market will grow from USD 6.33 billion in 2025 to USD 9.40 billion by 2033, registering a CAGR of 5.5%.

• Key Market Trends: Quadrivalent vaccines are gaining preference due to their broad protection and cost-efficiency, contributing to over 60% of new vaccine production by 2030.

• Key Market Drivers: Rising global influenza cases are driving vaccine demand, accounting for over 40% of new immunization initiatives during the forecast period.

• Technological Advancements: Streamlined production methods and improved viral strain prediction tools are reducing development times by nearly 20% compared to traditional approaches.

• Regional Growth: North America dominates the market with approximately 37% share, led by high infection rates, strong government funding, and public vaccine awareness.

• Type Segmentation: Quadrivalent vaccines hold the largest share at around 65% due to their wider protection against four virus strains, Trivalent vaccines maintain a 35% share, primarily used in seasonal applications with lower strain coverage.

• Application Segmentation: Children aged 6 months to 3 years represent the leading application segment with ~55% market share, driven by early immunization programs. The >3 years age group accounts for ~45% share, driven by school immunization and adult preventive care campaigns.

• Key Players: Sanofi leads the market with an estimated 26% share, followed by CSL, GSK, and AstraZeneca who collectively hold over 40% of the global market.

COVID-19 Impact

"Market Growth Boosted by Pandemic due to Increasing Demand for Vaccines"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The infection attacks the patients who are afflicted from respiratory systems problems increase the number of influenza cases. The second phase of pandemic has affected many patients who had survived the COVID-19 virus and many others. This had raised the demand for the vaccine and consequently enhanced the market growth. Hence, the COVID-19 has positive impact on this market notably because the increase in the demand for the vaccines.

LATEST TRENDS

There is an increase in demand and preference for quadrivalent vaccines by doctors and experts. The manufacturing cost is less which makes this vaccine cost-effective and easily available in the hospitals and clinics. It will work for four different types of viruses.

PANDEMIC INFLUENZA VACCINE MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

• Trivalent Influenza Vaccine: The trivalent influenza vaccine is a vaccine which can protect three different types of influenza viruses. It is formulated yearly to and used commonly for the seasonal flu.

• Quadrivalent Influenza Vaccine: The quadrivalent influenza vaccine is formulated to fight and protect against four types of influenza viruses which include two types of A influenza virus and other two types of B influenza virus.

By Application

Based on application the market can be categorized 6 Months to 3 Years, > 3 Years

• 6 Months to 3 Years: This is the application segment that dominates the market. As the vaccination doses are given to children from the 6 months old to 3 years old for protecting them from early age influenza disease.

• > 3 Years: This vaccine is also compulsory for the children of age group greater than 3 years or more. This is to reduce the rate of hospitalization and death by influenza infection.

DRIVING FACTORS

"Increasing Influenza cases Propel the Market Extremely"

The driving factors for the Pandemic Influenza Vaccine Market Growth is due to the fast increasing number of cases of the influenza infection that increases demand for vaccines. Various age groups of people get affected by this flu such as infants, children, adults and old age peoples. It is found that every year billions of people get affected by the seasonal influenza virus. With such a high rate and severe level of infection among the people increased the demand of the vaccines at a higher level which propelled the market growth.

"Increasing Government Investment Enhanced the Market Growth"

The other factor for the market growth is the increasing number of investments in this concerning area by the government. With the assistance and support of government investments have increased the capabilities of many companies to produce vaccines. There are some major companies who are investing in R&D for the production of advanced forms of vaccines which can target both the pandemic influenza as well as the seasonal influenza.

RESTRAINING FACTOR

"Longer Production Duration Restrict the Market Growth"

For the production of quality, safe and efficacy vaccines, it is required to follow many stepwise procedures which take longer time for the production of final vaccines. The stepwise procedures include data collection, analysis, research, trials and other, these all steps are time consuming which as a result delays in the production of the final vaccines. Also, due to lack of manufacturing units and instability of the biological properties affect the production efficacy. These are few restraining factors that hamper the market growth.

PANDEMIC INFLUENZA VACCINE MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America Dominates the Market due to Highly number of Infection Rate"

The North America region is dominating the Pandemic Influenza Vaccine Market Share due to the high number of affected people in this region. Government and major companies are investing in awareness campaigns and R&D so that people can be aware of such infections and understand the importance of the vaccines. The growing population of generic infection rate drives the market growth in this region.

KEY INDUSTRY PLAYERS

Many prominent industry players are operating in this market focused on growth strategies such as new product launch, approval of products, patents, and other. However, there are many companies in the market that use some techniques such as merger, acquisitions, partnership for producing and developing new products and stay ahead in the market.

List of Market Players Profiled

• Sanofi (France)
• CSL (Australia)
• GSK (U.K.)
• Viatris (U.S.)
• AstraZeneca (U.K.)
• Hualan Bio (China)
• Changchun Institute of Biological (China)
• Sinovac (China)
• BCHT (China)
• Jiangsu GDK (China)
• KM Biologics (Japan)

INDUSTRIAL DEVELOPMENT

March 2022: Sanofi, in Australia, has launched a high-dose influenza vaccine named Fluzone. This vaccine can protect from four strains of the various in Australia.

REPORT COVERAGE

This report is based on historical analysis and forecast calculation that aims to help readers get a comprehensive understanding of the global pandemic influenza vaccine market from multiple angles, which also provides sufficient support to readers’ strategy and decision-making. Also, this study comprises a comprehensive analysis of SWOT and provides insights for future developments within the market. It examines varied factors that contribute to the growth of the market by discovering the dynamic categories and potential areas of innovation whose applications may influence its trajectory in the upcoming years. This analysis encompasses both recent trends and historical turning points into consideration, providing a holistic understanding of the market’s competitors and identifying capable areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.